Arca
Skip to content

Systemic sclerosis

Drug research and approvals for systemic sclerosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 154 studies of systemic sclerosis are recruiting on ClinicalTrials.gov, Health Canada has authorized 26 drug trials for it since 2013, and FDA has 2 approved and 51 open orphan designations naming it.

  • Recruiting worldwide: 154
  • Trials authorized in Canada: 26
  • FDA orphan approvals: 2
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 154 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 26; search them all in Canada trials
May 12, 2026Immunomodulatory maintenance therapy post-autologous hematopoietic stem cell transplantation for prevention of systemic sclerosis relapse: a pilot randomized…MYCOPHENOLATEOTTAWA HOSPITAL RESEARCH INSTITUTEPending
Apr 23, 2026A double-blind, randomised, placebo-controlled trial evaluating the efficacy and safety of oral nerandomilast treatment in patients with systemic sclerosis…NERANDOMILAST (BI 1015550)BOEHRINGER INGELHEIM (CANADA) LTD LTEEPending
Mar 6, 2026A phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of bms-986353, cd19-targeted nex-t car t cells, versus standard of care…BMS-986353 (CC-97540) / ROACTEMRA (TOCILIZUMAB) / TRUXIMA (TRITUXIMAB) /…Bristol-Myers SquibbPending
Sep 23, 2025A phase¿2, multi-center study consisting of a randomized, double-blind, placebo-controlled period, followed by an open-label extension period, to assess the…TIBULIZUMAB (ZB-106)ZURA BIO INC.Closed
Aug 20, 2025An open-label study to investigate the long-term safety and efficacy of belimumab in adults with interstitial lung disease (ild) associated with systemic…BENLYSTAGSKPending
Dec 20, 2024A phase II, multi-part, three-year, randomized, open-label, assessor-blinded, active-controlled, multicenter study to evaluate the efficacy and safety of…YTB323 (RAPCABTAGENE AUTOLEUCEL)Novartis Pharmaceuticals CorporationPending
Jul 23, 2024Conquest platform clinical study for conquering scleroderma: a multicenter, double-blind, randomized, placebo-controlled, phase 2b platform clinical study to…NERANDOMILAST (BI 1015550)/ AMLITELIMAB (SAR445229)SCLERODERMA RESEARCH FOUNDATION, INC.Closed
Aug 28, 2023Randomized double-blind placebo-controlled clinical trial to assess the efficacy of mycophenolate mofetil in subclinical interstitial lung disease associated…MYCOPHENOLATESANTÉ QUÉBEC¿- CENTRE HOSPITALIER DE L’UNIVERSITÉ DE MONTRÉALOngoing
Aug 24, 2023A phase 2/3, randomized, double-blind, placebo, controlled, parallel-group study to evaluate the efficacy and safety of belimumab administered subcutaneously…BELIMUMABGSKPending
May 31, 2023A multicenter, randomized, parallel-group, double-blind, two¿ arm, phase III study to evaluate the safety and efficacy of anifrolumab compared with placebo in…SAPHNELOAstraZeneca Pharmaceuticals LPOngoing

FDA Orphan Designations

Approved first, then open designations, newest first; 15 of 53
Mar 4, 2021Actemraslowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung diseaseGenentech, Inc.Approved
Sep 6, 2019OFEVOFEV is indicated to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated interstitial lung…Boehringer Ingelheim Pharmaceuticals, Inc.Approved
Aug 17, 2026botulinum toxin type A (BTX-A)treatment of systemic sclerosis (SSc)ARCK Biologics, INC.Designated
Mar 9, 2026nerandomilasttreatment of systemic sclerosisBoehringer Ingelheim Pharmaceuticals, Inc, (BIPI)Designated
Jan 13, 2026nemolizumabtreatment of systemic sclerosisGalderma Research and Development, LLCDesignated
Dec 19, 2025autologous CD3+ T cells expressing CD19 chimeric antigen…treatment of systemic sclerosisJuno Therapeutics, Inc., a subsidiary of Bristol Myers SquibbDesignated
Oct 16, 2025blinatumomabtreatment of systemic sclerosisAmgen Inc.Designated
Aug 11, 20252-[1-(3-{6-[(1E)-(hydroxyimino)methyl]-5-methyl-4-oxo-7-prop…treatment of digital ulcers in systemic sclerosisTopadur Pharma AGDesignated
Jan 31, 2025artesunatetreatment of systemic sclerosisArtasome Therapeutics, LLCDesignated
Oct 18, 2024anti-ephrinB2 humanized IgG1 monoclonal antibodytreatment of systemic sclerosis (SSc)Mediar Therapeutics, Inc.Designated
Sep 20, 2024autologous anti-CD19 CAR T cell immunotherapytreatment of systemic sclerosisKyverna Therapeutics, Inc.Designated
Aug 19, 2024cilnidipinetreatment of systemic sclerosisAisa Pharma Inc.Designated
Aug 5, 2024(E)-N-(6-(piperidin-1-ylmethyl)-1-propyl-1,3-dihydro-2H-benz…Treatment of systemic sclerosisEydisBio, Inc.Designated
Mar 21, 2024pyridine derivative containing pyridazine that inhibits…Treatment of Systemic SclerosisBoehringer Ingelheim Pharmaceuticals, Inc.Designated
Mar 21, 2024small synthetic peptide based on a sequence found in the…Treatment of Systemic SclerosisBLR Bio LLCDesignated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.